Improving long-term medication adherence for HIV treatment
INcentives and ReMINDers to Improve Long-term Medication Adherence
This study is testing whether daily text messages and rewards can help people starting HIV treatment stick to their medication plan over the long term.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 550 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Rand Academic / other |
| Locations | 1 site (Kampala) |
| Trial ID | NCT06949774 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance long-term adherence to antiretroviral treatment (ART) among individuals starting therapy for HIV. It employs a Sequential, Multiple Assignment, Randomized Trial (SMART) design to test the effectiveness of daily text messages and incentivization strategies in promoting medication adherence. Participants will be randomized to receive either standard care or daily text messages, with those showing low adherence being re-randomized to receive various incentive schemes. The study will monitor adherence over 18 months to identify the most effective and cost-efficient intervention strategies.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have recently started ART and can communicate in English or Luganda.
Not a fit: Patients who are not mentally fit to consent or cannot consistently use the adherence measurement device will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve medication adherence among HIV patients, leading to better health outcomes and reduced transmission rates.
How similar studies have performed: Previous studies have shown promise in using behavioral economics and text messaging to improve medication adherence, suggesting this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and female clients age 18 and older. * Started ART at Mildmay or another clinic within the preceding 2 months * Able to speak and understand either English or Luganda. * Have their own cell phone or have consistent access to someone else's phone. * Willing to receive daily text messages for the 6 months of intervention duration. * Willing and able to use the WisePill device distributed for adherence verification for the duration of the study. Exclusion Criteria: * Not mentally fit to consent. * Language other than Luganda or English. * Not willing to consistently use the Wisepill device for adherence measurement.
Where this trial is running
Kampala
- Mildmay Uganda — Kampala, Uganda (Recruiting)
Study contacts
- Principal investigator: Sebastian Linnemayr, Ph.D — Rand
- Study coordinator: Yvonne Karamagi Site Principal Investigator
- Email: yvonne.karamagi@mildmay.or.ug
- Phone: +256312210200
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.